{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:46:49Z","timestamp":1793371609102,"version":"4.5.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tapinarof is an aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) and psoriasis. While common adverse events include headache and folliculitis, comedones and perifollicular hyperpigmentation are under-recognized. Here, we report eight patients with AD or psoriasis who developed comedones and\/or perifollicular hyperpigmentation during therapy. Lesions developed primarily at application sites; however, in one patient, lesions occurred at a distant site. Lesions appeared on the face in six patients, the legs in one and the arms in one. Time of onset ranged from 1 to 8 months after initiation of tapinarof therapy. Tapinarof was discontinued in all cases. Three patients were treated with topical adapalene\/benzoyl peroxide, with partial improvement in one and minimal improvement in two. One patient showed gradual improvement without additional treatment, whereas the remaining five showed no or minimal improvement during follow-up. Our cases provide important information on under-recognized adverse events during tapinarof therapy.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag121","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:57:09Z","timestamp":1782860229000},"page":"823-827","source":"Crossref","is-referenced-by-count":1,"title":["Localized comedones and perifollicular hyperpigmentation during tapinarof cream therapy: a case series"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-7167","authenticated-orcid":false,"given":"Yusuke","family":"Sano","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-2381","authenticated-orcid":false,"given":"Yasuaki","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Funai","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Hamamatsu Rosai Hospital , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026092919520526100_vzag121-B1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026092919520526100_vzag121-B2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092919520526100_vzag121-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review","volume":"154","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026092919520526100_vzag121-B4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215424","article-title":"Aryl hydrocarbon receptor in atopic dermatitis and psoriasis","volume":"20","author":"Furue","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026092919520526100_vzag121-B5","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/1346-8138.17451","article-title":"Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials","volume":"51","author":"Igarashi","year":"2024","journal-title":"J Dermatol"},{"key":"2026092919520526100_vzag121-B6","article-title":"Real-world effectiveness and safety of tapinarof 1% cream in psoriasis: an observational study from Bangladesh","volume":"18","author":"Huq","year":"2026","journal-title":"Cureus"},{"key":"2026092919520526100_vzag121-B7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clindermatol.2016.10.007","article-title":"Drug-induced acne","volume":"35","author":"Kazandjieva","year":"2017","journal-title":"Clin Dermatol"},{"key":"2026092919520526100_vzag121-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clindermatol.2013.05.035","article-title":"Periorbital (eyelid) dermatides","volume":"32","author":"Wolf","year":"2014","journal-title":"Clin Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/823\/70411912\/vzag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/823\/70411912\/vzag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:52:13Z","timestamp":1790725933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/5\/823\/8748421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":8,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag121","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,31]]}}}